Bookmark

Add to MyYahoo RSS

DePuy Orthopaedics News

News on DePuy Orthopaedics (Ticker: JNJ) continually updated from thousands of sources around the net.

16 hrs ago | Forbes.com

The Best Blood Cancer Drug Launch Ever?

Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets.

Comment?

Related Topix: Startups, Pharmacyclics, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

22 hrs ago | Law Firm Newswire

First Two DePuy Pinnacle Cases Trial-Ready by September 1, Notes Rottenstein Law Group LLP

Rockville Centre, NY August 1, 2014 - The Rottenstein Law Group LLP is currently representing plaintiffs with claims stemming from injuries allegedly caused by metal-on-metal DePuy Pinnacle hip replacement devices .

Comment?

Related Topix: Rockville Centre, NY, Medicine, Medical Equipment, Healthcare Industry

Thu Jul 31, 2014

Journal Watch

J&J Withdraws Power Morcellators

Johnson & Johnson is withdrawing its laparoscopic power morcellators from hospitals amid concerns that the devices may potentially spread undetected uterine sarcoma during fibroid removal and hysterectomy, the Wall Street Journal reports.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

TheStreet.com

Why Johnson & Johnson (JNJ) Stock Is Lower Today

The company plans to tell customers world-wide in a letter today to return the devices known as laparoscopic power morcellators, the Journal said, STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

National Public Radio

Senate Antitrust Panel Eyes Contact Lens Pricing Policies

Under "UPP," or universal pricing policies, manufacturers like Johnson & Johnson tell retailers they can't sell their contact lens below a certain price.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Wed Jul 30, 2014

The Washington Post

J&J Pulls From Market Hysterectomy Device Tied to Cancer Spread

Johnson & Johnson is pulling from the global market a device used during hysterectomies and other uterine procedures after reports that it may spread and accelerate the growth of undetected cancer inside women.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

The News Tribune

J&J withdraws fibroid treatment device from market

In April, J&J suspended sales of the devices, known as laparoscopic power morcellators, after the Food and Drug Administration discouraged doctors from using them.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

Mon Jul 28, 2014

Forbes.com

One Put, One Call Option To Know About for Johnson & Johnson

Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Thu Jul 24, 2014

GigaOM

Johnson & Johnson partners with Organovo to consider 3D-printing living tissue

The partnership centers around using bioprinted tissue to discover new drugs. The announcement comes ahead of Organovo's commercial launch later this year.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

The New Zealand Herald

What's best for baby?

Sharon Dowling, research and development manager for leading company Johnson & Johnson , shares her advice.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Wed Jul 23, 2014

Hispanic Business

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014

We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people.

Comment?

Related Topix: Biotech, Johnson and Johnson, Medicine, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls, LOC-AID Technologies, Medical Equipment, Hospital Administration, St Peters Health Care Services

Tue Jul 22, 2014

The Motley Fool

3 Quotes From Johnson & Johnson's Conference Call You Need to Read

Here are three quotes from the call and some commentary about why they're so important.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, OrthoClinical Diagnostics, Medical Equipment, Hospital Administration, St Peters Health Care Services

Mon Jul 21, 2014

TheStreet.com

Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend

The quarterly dividend is in line with the company's previous. The dividend is payable on Sept.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Wed Jul 16, 2014

AmericanBankingNews.com

Johnson & Johnson Given "Neutral" Rating at Zacks

's stock had its "neutral" rating reaffirmed by Zacks in a note issued to investors on Wednesday.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Forbes.com

Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May Face Competition Soon

Johnson & Johnson recently released its second quarter results. While the company beat consensus estimates, its stock fell slightly due to a weaker-than-expected outlook for the second half of 2014.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, OrthoClinical Diagnostics, Medical Equipment, Hospital Administration, St Peters Health Care Services

Morningstar

J&J's Strong 2Q Led by Pharmaceuticals

Johnson & Johnson reported strong second-quarter results that exceeded both our and consensus expectations largely because of stronger-than-expected pharmaceutical sales.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

CNN

Americans stock up on Tylenol, baby products

Americans have also been stocking up on anti-smoking aids, baby products, Aveeno skin care products and even Listerine mouthwash, according to the company.

Comment?

Related Topix: Smoking, Medicine, Health, Johnson & Johnson, Biotech, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

Tue Jul 15, 2014

TheStreet.com

Johnson & Johnson Beats on EPS but Sags on a Technical Basis

The large-cap pharmaceutical company also beat on revenue and raised full-year guidance.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

HAPPI/Household & PP Industry

Q2 Sales Rise at J&J

Johnson & Johnson posted a 9.1% increase in sales of $19.5 billion for the second quarter of 2014.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

Reuters

J&J beats forecasts, helped by new hepatitis C drug

Johnson & Johnson reported sharply better-than-expected quarterly revenue and earnings, fueled by strong sales of newer prescription drugs, including its Olysio treatment for hepatitis C. The diversified healthcare company on Tuesday said it earned $4.33 billion, or $1.51 per share, in the second quarter.

Comment?

Related Topix: Food, J and J Snack Foods, Hepatitis, Medicine, Health, Johnson & Johnson, Biotech, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••